Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Hot Topics of the Day|PHGKB
Search PHGKB:

Archive

Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.

Sign up MyPHGKB to receive the daily hot topic email alert.

Search Archive:
Archived Hot Topics of the Day By Date
23 hot topic(s) found with the query "Antidepressants"

AI-assisted prediction of differential response to antidepressant classes using electronic health records.
Yi-Han Sheu et al. NPJ Digit Med 2023 4 (1) 73 (Posted: Apr 27, 2023 8AM)

Antidepressant selection is largely a trial-and-error process. We used electronic health record (EHR) data and artificial intelligence (AI) to predict response to four antidepressants classes (SSRI, SNRI, bupropion, and mirtazapine) 4 to 12 weeks after antidepressant initiation. The final data set comprised 17,556 patients. We show that antidepressant response can be accurately predicted from real-world EHR data with AI modeling, and our approach could inform further development of clinical decision support systems for more effective treatment selection.

Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder.
Joas Erik et al. The pharmacogenomics journal 2022 11 (Posted: Nov 06, 2022 8AM)

We used Swedish national registry data 2005–2017 on dispensed medications and inpatient care to estimate risks for early-treatment persistence, treatment discontinuation, switching to a new antidepressant medication, and mania within 3 months of treatment initiation in patients treated with citalopram, escitalopram, sertraline, amitriptyline, and clomipramine. Metabolic phenotypes of CYP2C19 were not robustly associated with the investigated treatment outcomes based on dispense patterns. Slower metabolism was associated with an increased risk of treatment emergent mania for sertraline (hazard ratio [HR]?=?1.3, 95% CI?=?1.04–1.62, p?=?0.02) and the tricyclic antidepressants amitriptyline and clomipramine (HR?=?1.46, 95% CI?=?1.05–2.02, p?=?0.024).

Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients
LB Ramsey et al, JAMA Network Open, December 14, 2020 (Posted: Dec 15, 2020 8AM)

In this prescribing data at 16 health systems representing approximately 2.9 million pediatric patients per year from 2011 to 2017, the annual prevalence of exposure to at least 1 Clinical Pharmacogenetics Implementation Consortium level A drug ranged from 7987 to 10?629 per 100?000 pediatric patients. The medications with the highest potential for actionability were analgesics, the antiemetic ondansetron, and antidepressants.

Associations between the 1438A/G, 102T/C, and rs7997012G/A polymorphisms of HTR2A and the safety and efficacy of antidepressants in depression: a meta-analysis
YS Wan et al, The Pharmacogenomics Journal, October 23, 2020 (Posted: Oct 24, 2020 10AM)

The correlations between hydroxytryptamine receptor 2A (HTR2A) gene polymorphisms (1438A/G, 102T/C, and rs7997012G/A) and the safety and efficacy of antidepressants in depression patients have been reported. This meta-analysis ascertained forty-two studies. Pooled analyses indicated significant associations of 1438A/G polymorphism and higher response.

In the race to use genetic tests to predict whether antidepressants will work, science might be getting left behind
R Robbins, StatNews, September 28, 2018 (Posted: Sep 29, 2018 0PM)

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
Hicks J Kevin et al. Clin. Pharmacol. Ther. 2015 May 13. (Posted: May 22, 2015 5PM)

RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response.
Hennings J M et al. Transl Psychiatry 2015 e538 (Posted: May 02, 2015 3PM)

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.
Biernacka J M et al. Transl Psychiatry 2015 e553 (Posted: May 02, 2015 3PM)

Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders.
Helton Sarah G et al. Pharmacogenomics 2015 Apr (5) 541-53 (Posted: May 02, 2015 3PM)

The Efficacies and Toxicities of Antidepressant Drugs in Clinics, Building the Relationship between Chemo-Genetics and Socio-Environments.
Lu Da-Yong et al. Cent Nerv Syst Agents Med Chem 2015 Apr 28. (Posted: May 02, 2015 3PM)

Genome-wide association studies in pharmacogenomics of antidepressants.
Lin Eugene et al. Pharmacogenomics 2015 Apr (5) 555-66 (Posted: May 02, 2015 3PM)

Check out genetic tests related to selective serotonin reuptake inhibitor toxicity
from the NIH Genetic Testing Registry Brand (Posted: Feb 22, 2015 2PM)

Is there a role for antidepressant and antipsychotic pharmacogenetics in clinical practice in 2014?
Mulsant Benoit H et al. Can J Psychiatry 2014 Feb (2) 59-61 (Posted: Feb 22, 2015 2PM)

From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.
Fabbri Chiara et al. Can J Psychiatry 2014 Feb (2) 62-75 (Posted: Feb 22, 2015 2PM)

Understanding the pharmacogenetics of selective serotonin reuptake inhibitors.
Fabbri Chiara et al. Expert Opin Drug Metab Toxicol 2014 Aug (8) 1093-118 (Posted: Feb 22, 2015 2PM)

Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians.
Zai Gwyneth et al. Pharmacogenomics 2014 Jun (8) 1147-57 (Posted: Feb 22, 2015 2PM)

Clinical Outcomes and Genome-Wide Association for a Brain Methylation Site in an Antidepressant Pharmacogenetics Study in Mexican Americans.
Wong Ma-Li et al. Am J Psychiatry 2014 Sep 15. (Posted: Feb 22, 2015 2PM)

Genetic prediction of antidepressant drug response and nonresponse in Korean patients.
Lim Shinn-Won et al. PLoS ONE 2014 (9) e107098 (Posted: Feb 22, 2015 2PM)

Genetic determinants of selective serotonin reuptake inhibitor related sexual dysfunction.
Stevenson James M et al. Pharmacogenomics 2014 Nov (14) 1791-1806 (Posted: Feb 22, 2015 2PM)

Identifying genetic loci associated with antidepressant drug response with drug-gene interaction models in a population-based study.
Noordam Raymond et al. J Psychiatr Res 2015 Jan 20. (Posted: Feb 22, 2015 2PM)

Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.
Altar C A et al. Pharmacogenomics J. 2015 Feb 17. (Posted: Feb 22, 2015 2PM)

CPIC Dosing Guideline for amitriptyline and CYP2C19, CYP2D6
The CPIC Dosing Guideline for amitriptyline recommends an alternative drug for CYP2D6 or CYP2C19 ultrarapid metabolizers and for CYP2D6 poor metabolizers. Consider a 50% dose reduction for CYP2C19 poor metabolizers and a 25% dose reduction for CYP2D6 intermediate metabolizers, 2013 (Posted: Feb 22, 2015 2PM)

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.
Hicks J K et al. Clin. Pharmacol. Ther. 2013 May (5) 402-8 (Posted: Feb 22, 2015 2PM)


Disclaimer: Articles listed in Hot Topics of the Day are selected by Public Health Genomics Branch to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
TOP